In hepatocytes and embryonic stem cells derived from mice with both REV-ERB alpha and beta genetically deleted, SR9009 still decreased cell viability and altered cellular metabolism and gene transcription. This primary study cautions against treating all SR9009 effects as selective REV-ERB activation; it does not establish an exercise benefit in humans.[1]
- Mechanistic selectivity and clinical efficacy are separate questions.
- This is a genetic knockout mouse-cell model; no whole-animal exercise or endurance outcome and no human data appear in this paper.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
· Retrieved the full text of the PNAS paper (PMC6589768) via a Europe PMC PDF mirror after the fullTextXML and BioC endpoints both returned 404; read the abstract, introduction and results narrative directly. Confirmed the abstract's language exactly and added the precise cell source (hepatocytes and embryonic stem cells derived from a conditional REV-ERB alpha/beta double-knockout mouse model) from the full text; upgraded verification from abstract-checked to passage-checked. No indexed correction or retraction found. A PubMed search for SR9009 human trial and SR9009 exercise endurance mouse returned no new whole-animal exercise study through the cutoff. Independent editorial review pending.